Sign in
Not yet recruitingNo phase

Nerve damage and stomach emptying problems in diabetes patients taking semaglutide

Compares gastric retention in diabetic patients on semaglutide, with and without neuropathy.

Key facts

Who runs it
Fudan University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention
Status
Not yet recruiting
People taking part
460 people, planned
Started
15 Sept 2025
Expected to end
15 Sept 2028
Type of study
Observational, 2 groups
Treatments tested
  • Esophagogastroduodenoscopy
Record updated
5 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with diabetes who take semaglutide and are having a stomach scope (gastroscopy). It compares people with nerve damage (neuropathy) and people without it.

Age
18 years and older
Sex
All sexes
Disease stage
Confirmed diabetes. General health class ASA I-II (healthy or mild disease that is under control). Neuropathy status checked within 2 weeks before gastroscopy.
Earlier treatment
Must have used semaglutide for at least 4 weeks without stopping before the scope. Must fast at least 8 hours and drink no water for at least 4 hours before gastroscopy.

Main reasons for not taking part

  • Hiatal hernia (part of the stomach pushes up into the chest)
  • Any past stomach surgery, such as gastrectomy or Roux-en-Y gastric bypass
  • Pregnancy
  • Not fit enough for a stomach scope
  • Judged by the study doctors as unable to take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Confirmed diagnosis of diabetes mellitus
  • Long-term use of semaglutide (for at least 4 weeks) without discontinuation prior to endoscopic examination
  • Age ≥ 18 years, with no restriction on sex
  • American Society of Anesthesiologists (ASA) physical status classification I-II
  • Fasting for at least 8 hours and no water intake for at least 4 hours prior to gastroscopy
  • Underwent assessment for both autonomic and peripheral neuropathy within 2 weeks prior to gastroscopy, with a clear determination of neuropathy status

Who cannot take part

  • History of hiatal hernia or any prior gastric surgery (including gastrectomy, Roux-en-Y gastric bypass, etc.)
  • Pregnancy
  • Medically unfit for gastrointestinal endoscopy
  • Deemed unsuitable for participation at the discretion of the investigators

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A prospective, single-center, observational study to compare the risk of gastric retention between the exposure group (with neuropathy) and non-exposure group (without neuropathy) in diabetic patients receiving uninterrupted semaglutide therapy

The 2 groups in the trial

  • Exposure group

    Diabetic patients with neuropathy receiving uninterrupted semaglutide therapy

    Treatment: Esophagogastroduodenoscopy

  • Non-exposure group

    Diabetic patients without neuropathy receiving uninterrupted semaglutide therapy

    Treatment: Esophagogastroduodenoscopy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention: A Single-Center, Prospective, Observational Study
Plain-language title
Nerve damage and stomach emptying problems in diabetes patients taking semaglutideGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
5 September 2025